Zika virus infection enhances future risk of severe dengue disease.


Journal

Science (New York, N.Y.)
ISSN: 1095-9203
Titre abrégé: Science
Pays: United States
ID NLM: 0404511

Informations de publication

Date de publication:
28 08 2020
Historique:
received: 08 04 2020
accepted: 16 07 2020
entrez: 29 8 2020
pubmed: 29 8 2020
medline: 26 9 2020
Statut: ppublish

Résumé

The Zika pandemic sparked intense interest in whether immune interactions among dengue virus serotypes 1 to 4 (DENV1 to -4) extend to the closely related Zika virus (ZIKV). We investigated prospective pediatric cohorts in Nicaragua that experienced sequential DENV1 to -3 (2004 to 2015), Zika (2016 to 2017), and DENV2 (2018 to 2020) epidemics. Risk of symptomatic DENV2 infection and severe disease was elevated by one prior ZIKV infection, one prior DENV infection, or one prior DENV infection followed by one ZIKV infection, compared with being flavivirus-naïve. By contrast, multiple prior DENV infections reduced dengue risk. Further, although high preexisting anti-DENV antibody titers protected against DENV1, DENV3, and ZIKV disease, intermediate titers induced by previous ZIKV or DENV infection enhanced future risk of DENV2 disease and severity, as well as DENV3 severity. The observation that prior ZIKV infection can modulate dengue disease severity like a DENV serotype poses challenges to development of dengue and Zika vaccines.

Identifiants

pubmed: 32855339
pii: 369/6507/1123
doi: 10.1126/science.abb6143
pmc: PMC8274975
mid: NIHMS1692374
doi:

Substances chimiques

Antibodies, Viral 0
Dengue Vaccines 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1123-1128

Subventions

Organisme : FIC NIH HHS
ID : D43 TW010540
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI106695
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI118610
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI099631
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI107731
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Références

Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):9294-9299
pubmed: 30150394
Clin Infect Dis. 2017 Oct 15;65(8):1260-1265
pubmed: 29017246
J R Soc Interface. 2013 Jul 03;10(86):20130414
pubmed: 23825116
PLoS Negl Trop Dis. 2017 May 15;11(5):e0005554
pubmed: 28505154
J Infect Dis. 2017 Dec 5;216(10):1196-1204
pubmed: 28968838
PLoS Negl Trop Dis. 2011 Nov;5(11):e1397
pubmed: 22087348
Nature. 2018 May;557(7707):719-723
pubmed: 29795354
Cell Rep. 2020 Apr 28;31(4):107569
pubmed: 32348760
Clin Infect Dis. 2017 Sep 15;65(6):877-883
pubmed: 28535184
PLoS Pathog. 2014 Oct 02;10(10):e1004386
pubmed: 25275316
Trop Med Int Health. 2011 Aug;16(8):936-48
pubmed: 21624014
Rev Med Virol. 2020 Jul;30(4):e2101
pubmed: 32101634
Rev Panam Salud Publica. 2017 Aug 21;41:e56
pubmed: 28902269
J Infect Dis. 2018 Jul 13;218(4):536-545
pubmed: 29618091
J Clin Microbiol. 1998 Sep;36(9):2634-9
pubmed: 9705406
Proc Natl Acad Sci U S A. 2018 Oct 16;115(42):10762-10767
pubmed: 30266790
Sci Transl Med. 2015 Sep 9;7(304):304ra141
pubmed: 26355030
Am J Epidemiol. 2009 Jul 1;170(1):120-9
pubmed: 19435864
PLoS Pathog. 2017 Aug 3;13(8):e1006487
pubmed: 28771605
Cell Host Microbe. 2018 Nov 14;24(5):731-742.e6
pubmed: 30439342
Am J Epidemiol. 2000 Nov 1;152(9):793-9; discussion 804
pubmed: 11085389
Am J Trop Med Hyg. 2005 Dec;73(6):1063-70
pubmed: 16354813
Nature. 2017 Jun 15;546(7658):406-410
pubmed: 28538727
Science. 2010 May 7;328(5979):745-8
pubmed: 20448183
PLoS Negl Trop Dis. 2013 Sep 26;7(9):e2462
pubmed: 24086788
J Infect Dis. 2004 Mar 15;189(6):990-1000
pubmed: 14999601
Am J Trop Med Hyg. 1958 Sep;7(5):561-73
pubmed: 13571577
PLoS Negl Trop Dis. 2013 Aug 08;7(8):e2357
pubmed: 23951377
JCI Insight. 2020 Feb 13;5(3):
pubmed: 31910161
Mem Inst Oswaldo Cruz. 1990 Jul-Sep;85(3):347-51
pubmed: 2134709
J Infect Dis. 2015 Dec 1;212(11):1743-51
pubmed: 25980035
Nat Med. 2020 Feb;26(2):228-235
pubmed: 32015557
PLoS Pathog. 2010 Feb 12;6(2):e1000790
pubmed: 20168989
Am J Trop Med Hyg. 2016 Jun 1;94(6):1342-7
pubmed: 27022151
Nat Commun. 2019 Sep 20;10(1):4316
pubmed: 31541110
Science. 2017 Nov 17;358(6365):929-932
pubmed: 29097492
PLoS Med. 2019 Jan 22;16(1):e1002726
pubmed: 30668565
J Infect Dis. 2019 Jan 7;219(2):223-233
pubmed: 30085051
Trop Med Int Health. 2006 Jun;11(6):935-42
pubmed: 16772016
Nat Commun. 2019 Feb 26;10(1):938
pubmed: 30808875
J Infect Dis. 2014 Feb 1;209(3):360-8
pubmed: 23964110
Am J Trop Med Hyg. 2009 Aug;81(2):287-92
pubmed: 19635885
Am J Epidemiol. 1984 Nov;120(5):653-69
pubmed: 6496446
Nat Commun. 2017 Jun 23;8:15674
pubmed: 28643775
Nat Commun. 2017 Nov 13;8(1):1459
pubmed: 29129917
J Infect Dis. 2020 May 11;221(11):1846-1854
pubmed: 32236481
Science. 2016 Aug 19;353(6301):823-6
pubmed: 27417494
Am J Trop Med Hyg. 1999 Dec;61(6):893-7
pubmed: 10674666
PLoS Negl Trop Dis. 2014 Oct 16;8(10):e3230
pubmed: 25329173
PLoS Pathog. 2019 Aug 1;15(8):e1007766
pubmed: 31369649
Annu Rev Med. 2019 Jan 27;70:121-135
pubmed: 30388054
Adv Exp Med Biol. 2018;1062:63-76
pubmed: 29845525
Science. 2017 Apr 14;356(6334):175-180
pubmed: 28360135
J Clin Virol. 2016 May;78:57-61
pubmed: 26991052
Annu Rev Immunol. 2018 Apr 26;36:279-308
pubmed: 29345964
Cell Host Microbe. 2018 Nov 14;24(5):743-750.e5
pubmed: 30439343
Am J Trop Med Hyg. 1989 Apr;40(4):444-51
pubmed: 2712199
Science. 2017 Jan 27;355(6323):395-398
pubmed: 28126818
Virology. 2018 Feb;515:191-202
pubmed: 29304471
J Infect Dis. 1979 Oct;140(4):527-33
pubmed: 117061

Auteurs

Leah C Katzelnick (LC)

Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA.

César Narvaez (C)

Sustainable Sciences Institute, Managua, Nicaragua.

Sonia Arguello (S)

Sustainable Sciences Institute, Managua, Nicaragua.

Brenda Lopez Mercado (B)

Sustainable Sciences Institute, Managua, Nicaragua.

Damaris Collado (D)

Sustainable Sciences Institute, Managua, Nicaragua.

Oscarlett Ampie (O)

Sustainable Sciences Institute, Managua, Nicaragua.

Douglas Elizondo (D)

Sustainable Sciences Institute, Managua, Nicaragua.

Tatiana Miranda (T)

Sustainable Sciences Institute, Managua, Nicaragua.

Fausto Bustos Carillo (F)

Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA.

Juan Carlos Mercado (JC)

Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua.
Sustainable Sciences Institute, Managua, Nicaragua.

Krista Latta (K)

Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA.

Amy Schiller (A)

Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA.

Bruno Segovia-Chumbez (B)

Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.

Sergio Ojeda (S)

Sustainable Sciences Institute, Managua, Nicaragua.

Nery Sanchez (N)

Sustainable Sciences Institute, Managua, Nicaragua.

Miguel Plazaola (M)

Sustainable Sciences Institute, Managua, Nicaragua.

Josefina Coloma (J)

Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA.

M Elizabeth Halloran (ME)

Department of Biostatistics, University of Washington, Seattle, WA, USA.
Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Lakshmanane Premkumar (L)

Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.

Aubree Gordon (A)

Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA.

Federico Narvaez (F)

Sustainable Sciences Institute, Managua, Nicaragua.

Aravinda M de Silva (AM)

Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.

Guillermina Kuan (G)

Centro de Salud Sócrates Flores Vivas, Ministry of Health, Managua, Nicaragua.
Sustainable Sciences Institute, Managua, Nicaragua.

Angel Balmaseda (A)

Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua.
Sustainable Sciences Institute, Managua, Nicaragua.

Eva Harris (E)

Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA. eharris@berkeley.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH